We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




In Home Healthcare Leadership Bid, Philips To Acquire Respironics for $5.1 Billion

By HospiMedica staff writers
Posted on 03 Jan 2008

In a move that would elevate the company to leadership ranks in the fast-growing home healthcare sector, Philips, already a major player in the medical imaging and patient monitoring sectors, has agreed to acquire Respironics, a market leader in the respiratory care sector, for a total price of US$ 5.1 billion.

The home healthcare market is expected to grow at a very robust pace, at rates sufficient to focus the attention of companies in the healthcare business to that sector. More...

Philips' Home Healthcare business already supports nearly a million seniors in their homes or living facilities in the US and Canada alone. With the Respironics acquisition, Philips intends to strengthen its home healthcare offerings by adding new product categories, and benefit from the cost synergies derived from the merger. In addition, the Respironics deal is well inline with Philips' earlier acquisitions of home healthcare companies such as Lifeline Systems, Health Watch, and Raytel Cardiac services.

Respironics is a world leader in the treatment of Obstructive Sleep Apnea (OSA), a disorder typified by the repeated cessation of breathing during sleep. The number of OSA sufferers in the US has been estimated at 18-20 million, only about a fifth of which have been diagnosed. Recent research points to a link between OSA and stroke, heart disease, and diabetes. Respironics is also well placed in noninvasive ventilation in the home market segment as well as invasive and noninvasive ventilation, respiratory monitoring, neonatal products, and respiratory drug delivery in the hospital sector.

Philips will acquire all outstanding shares of Respironics for approximately US$5.1 billion in cash--almost a third above the Respironics average closing share price. Upon closing, Respironics will become the headquarters for the Home Health Care Solutions group within Philips Healthcare, and Respironics' senior operating management is expected to remain and continue to lead the business. The transaction, subject to customary conditions, is expected to close during the first quarter of 2008. Industry analysts have praised the acquisition as a good strategic move.

Steve Rusckowski, CEO of Philips Healthcare and member of the Board of Management of Royal Philips said, "A core part of Philips' healthcare strategy is to take a leading position in the high-growth sector of home healthcare.”

Respironics (Murrysville, PA, USA; www.respironics.com) is a developer, manufacturer and distributor of products that serve the sleep and respiratory markets. With net sales of $1.2 billion in 2007, Respironics markets its products in over 140 countries and employs over 5,300 people worldwide.

Royal Philips Electronics (Amsterdam, The Netherlands; www.philips.com) is a global leader in healthcare, lighting and consumer lifestyle products. Philips employs about 128,000 people in over 60 countries worldwide. With sales of about $40 billion, the company is a market leader in medical imaging and patient monitoring systems, energy efficient lighting solutions, personal care and home appliances, as well as consumer electronics.




Related Links:
Royal Philips Electronics of the Netherlands
Respironics

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.